T1	intervention 0 15	Zoledronic acid
T2	condition 50 59	bone loss
T3	eligibility 63 156	premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer
T4	location 176 184	Austrian
T7	duration 779 786	3 years
T8	No-of-participants 969 985	Four hundred one
T9	outcome 1107 1124	overall bone loss
T5	outcome-Measure 920 923	BMD
T6	outcome 1213 1230	Overall bone loss
T10	outcome 1460 1463	BMD
